TARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron's Board
"Today's announcement demonstrates our strong commitment to strategic refreshment of the Board, a focus on the recruitment of new directors to complement the overall mix of skills, experience and perspectives, and further enhancement of the Board's diversity," said Christine Poon, Lead Independent Director of Regeneron's Board.
"I am thrilled to join Regeneron's Board of Directors," said Dr. Guarini."Regeneron's science-driven mission and prioritization of homegrown technologies resonates strongly with me, and I look forward to adding my technology and business experience to foster Regeneron's innovative approach in all areas of the business."
"Regeneron has been moving biotechnology innovation forward for over three decades, and I am excited to work alongside a talented team of physician-scientists guided by patient impact," said Dr. Schenkein."The company approaches medicine with a unique mix of entrepreneurial spirit, scientific rigor and deep medical knowledge.
"It has been a great privilege to be a member of Regeneron's Board for close to 12 years," said Dr. Tessier-Lavigne."Throughout that time, I have been continually inspired by the quality and the intensity of the science at Regeneron, and the drive that permeates the entire company to create therapies and cures for patients suffering from poorly treated diseases.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
JPMORGAN stuft APPLE INC auf 'Overweight'NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Apple vor der Einführung neuer Produkte in der kommenden Woche von 235 auf 230 US-Dollar gesenkt, aber die Einstufung auf 'Overweight'
Baca lebih lajut »
- The Vanguard Group, Inc.: Horizon Therapeutics plcDJ Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 08-Sep-2023 / 12:58 GMT/BST=----------------------------------------------------------------------------------------------------------------------
Baca lebih lajut »
Target Global Acquisition I Corp. kündigt Verlängerung der Frist für den Abschluss des ersten Geschäftszusammenschlusses anBerlin (ots/PRNewswire) - Target Global Acquisition I Corp. (Nasdaq: TGAA) (das 'Unternehmen') gab heute bekannt, dass sein Board of Directors (das 'Board') auf Antrag von Target Global Sponsor Ltd. (der
Baca lebih lajut »